Market Capitalization (Millions $) |
1,013 |
Shares
Outstanding (Millions) |
174 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-195 |
Cash Flow (TTM) (Millions $) |
-126 |
Capital Exp. (TTM) (Millions $) |
11 |
Autolus Therapeutics Plc
Autolus Therapeutics Plc is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation, programmed T-cell therapies for the treatment of cancer. They utilize their proprietary technology to engineer cell therapies with improved safety and efficacy compared to traditional approaches. Autolus is known for its innovative approach to developing personalized therapies that target and destroy cancer cells, while leaving healthy cells intact. The company's pipeline includes a range of product candidates targeting various types of blood cancers, including B-cell malignancies and multiple myeloma. Autolus Therapeutics aims to revolutionize cancer treatment by harnessing the power of the immune system to effectively and selectively eliminate cancer cells.
Company Address: The Mediaworks London 0
Company Phone Number: 3829 6230 Stock Exchange / Ticker: NASDAQ AUTL
|